Xinyang Vocational and Technical College, Xinyang, China.
Department of Hepatobiliary Surgery, Baoji Hospital of Traditional Chinese Medicine, Baoji, Shaanxi, China.
Cell Mol Biol (Noisy-le-grand). 2022 Feb 4;67(5):302-308. doi: 10.14715/cmb/2021.67.4.41.
This study aimed to investigate the levels of cancer antigen 19-9 (CA19-9), neutrophil/lymphocyte ratio (NLR) and systemic immune-inflammatory index (SIRI) in patients with pancreatic cancer with different clinical features and their clinical value. For this purpose, 78 patients with pancreatic cancer treated in our hospital from January 2018 to January 2021 were divided into two groups according to the NLR and SIRI calculated by blood routine and biochemical examination before operation. To observe and analyze the relationship between serum CA19-19 levels, clinical features and NLR and SIRI values in patients with different clinical stages and tumor diameter, and the diagnostic value of CA19-9, NLR and SIRI in pancreatic cancer. The results showed that the level of serum CA19-9 in patients with stage IV pancreatic cancer was significantly higher than that in patients with stage I, II and III, and the level of CA19-9 in patients with stage III was higher than that in patients with stage I and II, and the level of CA19-9 in patients with stage II was higher than that in patients with stage I. The level of CA19-9 in patients with pancreatic cancer with tumor diameter ≥ 5cm was significantly higher than that in patients with tumor diameter < 5cm. The percentage of patients with age ≤ 60 years old in high NLR group (83.78%) was significantly higher than that in low NLR group (63.41%), and the rate of patients with tumor diameter ≥ 5cm in the high SIRI group (54.05%) was significantly higher than that in low NLR group (26.83%). The rate of patients with tumor diameter ≥ 5cm in the high SIRI group (61.92%) was significantly higher than that in the low SIRI group (31.58%). Among the single indexes, the sensitivity of CA19-9 in the diagnosis of pancreatic cancer was the highest (93.10%). The specificity of Siri in the diagnosis of pancreatic cancer was 89.70%. The sensitivity and specificity of combined detection were 89.7% and 70.00%, respectively. In general, the level of serum CA19-9 in patients with pancreatic cancer increases gradually with the increase of clinical stage and tumor diameter. NLR value is related to patient age and tumor diameter, and SIRI value is related to tumor diameter. Combined detection of CA19-9, NLR and SIRI are of higher value in the early diagnosis of pancreatic cancer.
本研究旨在探讨不同临床特征的胰腺癌患者的癌抗原 19-9（CA19-9）、中性粒细胞/淋巴细胞比值（NLR）和全身免疫炎症指数（SIRI）水平及其临床价值。为此，根据术前血常规和生化检查计算的 NLR 和 SIRI，将我院 2018 年 1 月至 2021 年 1 月收治的 78 例胰腺癌患者分为两组。观察分析不同临床分期和肿瘤直径患者血清 CA19-19 水平、临床特征与 NLR 和 SIRI 值的关系，并探讨 CA19-9、NLR 和 SIRI 对胰腺癌的诊断价值。结果表明，IV 期胰腺癌患者血清 CA19-9 水平明显高于 I、II、III 期，III 期 CA19-9 水平高于 I、II 期，II 期 CA19-9 水平高于 I 期。肿瘤直径≥5cm 的胰腺癌患者 CA19-9 水平明显高于肿瘤直径<5cm 的患者。高 NLR 组（83.78%）年龄≤60 岁患者百分比明显高于低 NLR 组（63.41%），高 SIRI 组（54.05%）肿瘤直径≥5cm 患者比例明显高于低 NLR 组（26.83%）。高 SIRI 组（61.92%）肿瘤直径≥5cm 患者比例明显高于低 SIRI 组（31.58%）。单项指标中，CA19-9 对胰腺癌的诊断敏感性最高（93.10%）。Siri 对胰腺癌的诊断特异性为 89.70%。联合检测的敏感性和特异性分别为 89.7%和 70.00%。一般来说，胰腺癌患者血清 CA19-9 水平随临床分期和肿瘤直径的增加而逐渐升高。NLR 值与患者年龄和肿瘤直径有关，SIRI 值与肿瘤直径有关。CA19-9、NLR 和 SIRI 的联合检测对胰腺癌的早期诊断具有较高的价值。
